Group One Trading
TNGX icon

Group One Trading’s Tango Therapeutics TNGX Stock Holding History

Group One Trading’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,400
Closed -$9.47K – 9160
2025
Q2 		$7.17K Buy
+1,400
New +$3.46K ﹤0.01% 6916

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Group One Trading's TNGX Position: Q3 2025 in Review

Group One Trading sold out of Tango Therapeutics (TNGX) in Q3 2025, closing a stake of 1,400 shares — an estimated $9.47K sold.

Group One Trading first reported a position in TNGX in Q2 2025 and held it in 1 quarter. The position peaked at $7.17K in Q2 2025. 141 funds tracked by Wall St. Rank hold TNGX as of Q3 2025.

  • Group One Trading reported no remaining Tango Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 1,400 Tango Therapeutics shares in Q3 2025, an estimated $9.47K.
  • Group One Trading first reported a position in Tango Therapeutics in Q2 2025 and held it in 1 quarter.
  • Group One Trading's Tango Therapeutics position peaked at $7.17K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.